Surprising Results—

Most Angioplasties Unneeded, Study Finds

NEW ORLEANS, LA. (AP) — More than half a million people a year with chest pain are getting an unnecessary or premature procedure to unclog their arteries because drugs are just as effective, suggests a landmark study that challenges one of the most common practices in heart care.

The stunning results found that angioplasty did not save lives or prevent heart attacks in nonemergency heart patients.

An even bigger surprise: Angioplasty gave only slight and temporary relief from chest pain, the main reason it is done.

“By five years, there was really no significant difference” in symptoms, said Dr William Boden of Buffalo General Hospital in New York. “Few would have expected such results.”

He led the study and gave results this week at a meeting of the American College of Cardiology. They also were published online by the New England Journal of Medicine and will be in the April 12 issue.

Angioplasty remains the top treatment for people having a heart attack or hospitalized with worsening symptoms. But most angioplasties are done on a nonemergency basis, to relieve chest pain caused by clogged arteries crimping the heart’s blood supply.

Those patients now should try drugs first, experts say. If that does not help, they can consider angioplasty or bypass surgery, which unlike angioplasty, does save lives, prevent heart attacks, and give lasting chest pain relief.

In the study, only one-third of the people treated with drugs ultimately needed angioplasty or a bypass.

“You are not putting yourself at risk of death or heart attack if you defer,” and considering the safety worries about heart stents used to keep arteries open after angioplasty, it may be wise to wait, said Dr Steven Nissen, a Cleveland Clinic heart specialist and president of the College of Cardiology.

Why did angioplasty not help more?

It fixes only one blockage at a time whereas drugs affect all the arteries, experts said. Also, the clogs treated with angioplasty are not the really dangerous kind.

“Even though it goes against intuition, the blockages that are severe that cause chest pain are less likely to be the source of a heart attack than segments in the artery that are not severely blocked,” said Dr David Maron, a Vanderbilt University cardiologist who helped lead the new study.

About 1.2 million angioplasties are done in the United States each year. Through a blood vessel in the groin, doctors snake a tube to a blocked heart artery. A tiny balloon is inflated to flatten the clog and a mesh scaffold stent is usually placed.

The procedure already has lost some popularity because of emerging evidence that popular drug-coated stents can raise the risk of blood clots months later. The new study shifts the argument from which type of stent to use to whether to do the procedure at all.

It involved 2,287 patients throughout the United States and Canada who had substantial blockages, typically in two arteries, but were medically stable. They had an average of ten chest pain episodes a week — moderately severe.

About 40 percent had a prior heart attack more than three months previously.

“We deliberately chose to enroll a sicker, more symptomatic group” to give angioplasty a good chance to prove itself, Dr Boden said.

All were treated with medicines that improve chest pain and heart and artery health such as aspirin, cholesterol-lowering statins, nitrates, ACE inhibitors, beta-blockers, and calcium channel blockers. All also were counseled on healthy lifestyles — diet, exercise, and smoking cessation.

Half of the participants also were assigned to get angioplasty.

After an average of 4½ years, the groups had similar rates of death and heart attack: 211 in the angioplasty group and 202 in the medication group — about 19 percent of each.

Heart-related hospitalization rates were similar, too.

Neither treatment proved better for any subgroups like smokers, diabetics, or older or sicker people.

At the start of the study, 80 percent had chest pain. Three years into it, 72 percent of the angioplasty group was free of this symptom as was 67 percent of the drug group.

That means you would have to give angioplasties to 20 people for every one whose chest pain was better after three years —an unacceptably high ratio, Dr Nissen said.

After five years, 74 percent of the angioplasty group and 72 percent of the medication group were free of chest pain — “No significant difference,” Dr Boden said.

The study was funded by the US Department of Veterans Affairs, the Medical Research Council of Canada, and a host of drug companies. Stent makers refused to help pay for the research, said scientists who led the study.

The study renewed a heated animosity between doctors who perform angioplasty and other heart specialists.

In fact, one who does the procedures and who spoke at a meeting in New Orleans sponsored by stent maker Boston Scientific Corp (BSX) was responsible for the early release of the study’s results, which were not due out until March 27.

The study “was rigged to fail, and it did,” The Wall Street Journal quoted Dr Martin B Leon of Columbia University telling several hundred of his colleagues.

“A lot of people have been taking shots at us, and we need to go on the offense for awhile,” the Journal reported Dr Leon said.

He claimed to have inside knowledge of the results because he reviewed the study for the New England Journal of Medicine. The journal would not comment, saying the identity of its reviewers is confidential.

The cardiology college issued a statement saying it was “extremely disappointed” results were released prematurely, “betraying the confidentiality of the scholarly process and the professional integrity of the scientific community.”

The college “will be considering strong sanctions against the individual or individuals involved,” the statement said.

Shares of Boston Scientific were down $1.15, or nearly 8 percent, to $14.07 in Monday afternoon trading on the New York Stock Exchange. It was a nearly five-year low for the stock.

Dr Spencer King of Piedmont Hospital in Atlanta, a leading cardiologist who does many angioplasties, said he was disappointed in the study results.

“How many patients have interventions in which the only expectation is to reduce the use of nitroglycerin or to walk a bit faster? Most patients anticipate a better prognosis and might opt for an extended course of medical therapy if they believe they are not putting their life at excess risk,” he wrote in a recent editorial in an American Heart Association journal.

In an interview at the cardiology meeting, Dr King said he recently had surgery for back pain and did not expect permanent relief but added, “If it only held up for five years, I wouldn’t be happy about it.”

The new study “should lead to changes in the treatment of patients with stable coronary artery disease, with expected substantial health care savings,” Dr Judith Hochman of New York University wrote in an editorial in the journal.

Angioplasty costs $30,000 to $40,000. The drugs used in the study are almost all available in generic form.

Dr Maron, the Vanderbilt physician who helped lead the study, said people should give the drugs a chance.

“Often I think that patients are under the impression that unless they have that procedure done, they’re not getting the best of care and are at increased risk of having a heart attack and die,” he said. The study shows that is not true, he added.